DEC 18, 2017 5:38 PM PST

Next Generation Antibody Therapeutics

WRITTEN BY: Courtney Schaal

Antibodies have been gaining traction in the clinical drug pipeline for the past three decades, and have shown great efficacy and promise in many diseases involving immune response including chronic inflammation, cancer, and autoimmune diseases to name a few. According to a recent article written by Paul Carter and Greg Lazar from the Department of Antibody Engineering at Genentech Incorporated, in San Francisco California, there have been over 60 antibody based drugs approved for therapeutic use and are currently marketed with world-wide revenues of approximately 89 billion dollars in the United States. This amount of revenue is enough to grab your attention, as well as others in the drug production industry. Carter and Lazar also note that there are over 550 antibodies currently in clinical development, which includes more than 50 in phase III clinical trials, which is incredibly promising.

This makes antibodies for treatment of disease one of the most rapidly growing drug classes currently being pursued, and they have so far proven to have great effect. Antibodies that essentially act by some mechanism or another to aid immune cells to recognize tumor cells to destroy them and eradicate them from the body is one example of successful employment of antibody drugs that has exploded in the last several years. These include antibodies specific to antigens such as CTLA4, CD20, CD22, EGFR, CCR4, HER2, IL-1alpha, PD1, PDL1, RANKL, and VEGF – again – just to name a few. These acronyms each represent molecules that play a role in various types of cancer progression that when target can diminish the cancer. This also has been found to be effective in multiple cancer types such as leukemias, lymphomas, melanomas, colorectal, head and neck, lung, breast, skeletal, and even brain cancers – which is highly impressive considering that each of these cancer types is a disease unto itself having different driver mutations and mutational burdens. They all have one thing in common that is exploitable by antibodies therapeutically, however, and that is they can evade the immune system. Antibodies enable the immune system to once again recognize the tumor, which results in subsequent tumor cell killing. Antibody drugs are also in use for diseases such as multiple sclerosis, Crohn’s disease, ulcerative colitis, lupus, psoriasis, asthma, arthritis, and others which all have the commonality of an immune system component implicated in some aspect of the disease. Antibodies are even being studied for use in prevention of migraines. This is a pretty impressive list of diseases for which antibodies may prove effective drug strategies.

Currently, the new and emerging antibodies are being expanded and according to the article by Carter and Lazar, “novel mechanisms of action of antibodies and innovative targeting strategies that could extend their therapeutic applications, including antibody-drug conjugates, bispecific antibodies, and antibody engineering to facilitate more effective delivery” are underway. “These strategies could enable the pursuit of difficult to hit, less well understood or previously undruggable targets – the ‘high-hanging fruit’. So not just antibodies targeting disease drivers themselves or eliciting immune reponse to disease, but also arming such antibodies with other drugs to deliver directly to indicated sites, and also creating antibodies with dual-specificities to hit two targets, or creating new specificities all together. This is an exciting time for the world of antibody drug discovery, and should prove to have great implications for patients in the clinic.

Sources: Nature Reviews Drug Discovery, Pixabay, Youtube, Roche

Roche's summary of antibodies in medicine:

 

About the Author
You May Also Like
NOV 15, 2020
Drug Discovery & Development
Antidepressant May Prevent Worsening of COVID-19 Infections
NOV 15, 2020
Antidepressant May Prevent Worsening of COVID-19 Infections
  Researchers from the Washington University School of Medicine in St. Louis have found that fluvoxamine, a common ...
NOV 25, 2020
Immunology
The History of Vaccines
NOV 25, 2020
The History of Vaccines
Everyone worldwide is sitting with anticipation, waiting for the right vaccine candidate for the coronavirus outbreak, h ...
NOV 09, 2020
Drug Discovery & Development
Can Oxidants Slow Down Cellular Aging?
NOV 09, 2020
Can Oxidants Slow Down Cellular Aging?
Oxidants are reactive oxygen species known to be harmful to living organisms at high concentrations and have been linked ...
NOV 26, 2020
Cannabis Sciences
Women More Likely than Men to Swap Prescription Medication for Cannabis
NOV 26, 2020
Women More Likely than Men to Swap Prescription Medication for Cannabis
The stigma around cannabis usage is fading as cannabis laws become increasingly lax. Now, researchers from DePaul Univer ...
NOV 25, 2020
Drug Discovery & Development
Improving Drug Dissolution
NOV 25, 2020
Improving Drug Dissolution
When you take your medicine, it travels through the bloodstream and releases its effects. When the drug dissolves too fa ...
DEC 15, 2020
Cannabis Sciences
Could Cannabis Help in the Opioid Crisis?
DEC 15, 2020
Could Cannabis Help in the Opioid Crisis?
While cannabis is increasingly available for medicinal use, doctors largely remain unable to prescribe it to their patie ...
Loading Comments...